8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 5, 2026·SEC
Core Laboratories N.V.(CLB)Earnings, Financials & Key Ratios
CLB•NYSE
$11.02
16.2× P/E·Price updated Jun 27, 2026
AboutCore Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.Show more
- Revenue$527M+0.5%
- EBITDA$64M-13.6%
- Net Income$32M+1.3%
- EPS (Diluted)0.68+3.0%
- Gross Margin17.91%+6.1%
- EBITDA Margin12.06%-14.1%
- Operating Margin9.28%-17.0%
- Net Margin6.04%+0.8%
- ROE11.83%-8.1%
CLB Price & Volume
Core Laboratories N.V. (CLB) stock price & volume — 10-year historical chart
Loading chart...
Operational Volatility Challenges Core Laboratories' Margin Stability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Cyclical Revenue Volatility
Key Thesis Takeaways
- Core Laboratories faces significant headwinds as its high fixed-cost structure leads to extreme operating income sensitivity, evidenced by the collapse from $14.4 million in 2025Q4 to $1.9 million in 2026Q1.
- While the company has successfully reduced total debt from $215.4 million in 2023Q4 to $41.3 million in 2026Q1, the persistent revenue contraction and reliance on stock-based compensation—which reached $5.0 million in the most recent quarter—complicate the path to sustainable profitability.
- Investors should monitor whether the firm can stabilize its 16.2% gross margin in a volatile energy services market before committing capital to this asset-light model.
Verdict Logic
while the balance sheet has been deleveraged to a debt-to-equity ratio of 0.15, the lack of consistent earnings growth and the $5.0 million stock-based compensation expense in 2026Q1 suggest significant operational risks remain.
CLB Growth Metrics
Core Laboratories N.V. (CLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-4.07%
5 Years1.56%
3 Years2.44%
TTM1.34%
Profit CAGR
10 Years-12.05%
5 Years-
3 Years17.8%
TTM11.21%
EPS CAGR
10 Years-12.82%
5 Years-
3 Years17.42%
TTM8.93%
Return on Capital
10 Years11.8%
5 Years10.19%
3 Years11%
Last Year9.94%
CLB Recent Earnings
Core Laboratories N.V. (CLB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
$122M-1.0%
$123M
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.21+9.8%
$0.19
Rev
$138M+4.6%
$132M
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$0.22+15.8%
$0.19
Rev
$135M+4.6%
$129M
Q3 2025
Jul 23, 2025Metric
Actual
Est
EPS
$0.19+5.6%
$0.18
Rev
$130M-0.6%
$131M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.06vs $0.06+0.0% | $122Mvs $123M-1.0% |
| Q1 2026 | Feb 4, 2026 | $0.21vs $0.19+9.8% | $138Mvs $132M+4.6% |
| Q4 2025 | Oct 22, 2025 | $0.22vs $0.19+15.8% | $135Mvs $129M+4.6% |
| Q3 2025 | Jul 23, 2025 | $0.19vs $0.18+5.6% | $130Mvs $131M-0.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Core Laboratories N.V. (CLB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.02 | $507.45M | 16.21 | 0.51% | 6.04% | 11.83% | 0.36% | |
| $26.86 | $4.35B | 30.18 | -7.16% | 3.71% | 7.39% | — | |
| $12.90 | $558.71M | -10.32 | 1.41% | 11.52% | — | — | |
| $14.80 | $1.81B | 1897.44 | -12.13% | -1.05% | -1.43% | — | |
| $9.59 | $3.64B | -39.96 | -10.25% | -2.56% | -3.67% | — | |
| $5.89 | $1.31B | 39.27 | 14.95% | 1.2% | 1.91% | — |
Compare CLB vs Peers
Core Laboratories N.V. (CLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLB SEC Filings & Documents
Core Laboratories N.V. (CLB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CLB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLB Frequently Asked Questions
Core Laboratories N.V. (CLB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Core Laboratories N.V.'s revenue?
Core Laboratories N.V. (CLB) reported $524.7M in revenue for fiscal year 2025. This represents a 398% increase from $105.4M in 1996.
How fast is Core Laboratories N.V. growing?
Core Laboratories N.V. (CLB) grew revenue by 0.5% over the past year. Growth has been modest.
Is CLB profitable?
Yes, Core Laboratories N.V. (CLB) is profitable, generating $31.2M in net income for fiscal year 2025 (6.0% net margin).
Dividend & Returns
Does CLB pay dividends?
Yes, Core Laboratories N.V. (CLB) pays a dividend with a yield of 0.36%. This makes it attractive for income-focused investors.
What is CLB's return on equity?
Core Laboratories N.V. (CLB) has a return on equity (ROE) of 11.8%. This is reasonable for most industries.
What is Core Laboratories N.V.'s free cash flow?
Core Laboratories N.V. (CLB) generated $23.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.